Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey
- PMID: 24966712
- PMCID: PMC4069044
- DOI: 10.4137/CGast.S13125
Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey
Abstract
Background and aims: Inflammatory bowel diseases (IBD) are frequently associated with altered liver function tests (LFTs). The causal relationship between abnormal LFTs and IBD is unclear. The aim of our study was to evaluate the prevalence and etiology of LFTs abnormalities and their association with clinical variables in a cohort of IBD patients followed up in a single center.
Materials and methods: A retrospective review was undertaken of all consecutive IBD in- and outpatients routinely followed up at a single referral center. Clinical and demographic parameters were recorded. Subjects were excluded if they had a previous diagnosis of chronic liver disease. LFT abnormality was defined as an increase in aspartate aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), or total bilirubin.
Results: A cohort of 335 patients (179 males, mean age 46.0 ± 15.6 years) was analyzed. Abnormal LFTs were detected in 70 patients (20.9%). In most cases, the alterations were mild and spontaneously returned to normal values in about 60% of patients. Patients with abnormal LFTs were less frequently on treatment with aminosalicylates (22.8 vs. 36.6%, P = 0.04). The most frequent cause for transient abnormal LFTs was drug-induced cholestasis (34.1%), whereas fatty liver was the most frequent cause of persistent liver damage (65.4%). A cholestatic pattern was found in 60.0% of patients and was mainly related to older age, longer duration of disease, and hypertension.
Conclusions: The prevalence of LFT abnormalities is relatively high in IBD patients, but the development of severe liver injury is exceptional. Moreover, most alterations of LFTs are mild and spontaneously return to normal values. Drug-induced hepatotoxicity and fatty liver are the most relevant causes of abnormal LFTs in patients with IBD.
Keywords: drug-induced hepatotoxicity; fatty liver; inflammatory bowel disease; liver function tests.
Similar articles
-
Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.World J Gastroenterol. 2017 Jun 14;23(22):4102-4111. doi: 10.3748/wjg.v23.i22.4102. World J Gastroenterol. 2017. PMID: 28652663 Free PMC article.
-
Risk factors for abnormal liver function tests in patients with ileal pouch-anal anastomosis for underlying inflammatory bowel disease.Am J Gastroenterol. 2009 Oct;104(10):2467-75. doi: 10.1038/ajg.2009.343. Epub 2009 Jun 23. Am J Gastroenterol. 2009. PMID: 19550410
-
Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study.Health Technol Assess. 2013 Jul;17(28):i-xiv, 1-307. doi: 10.3310/hta17280. Health Technol Assess. 2013. PMID: 23834998 Free PMC article.
-
Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis.Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):13072-13088. doi: 10.26355/eurrev_202012_24215. Eur Rev Med Pharmacol Sci. 2020. PMID: 33378061
-
Liver function tests: what is the risk?J Insur Med. 2003;35(1):26-35. J Insur Med. 2003. PMID: 14694823 Review.
Cited by
-
Inflammatory bowel disease type influences development of elevated liver enzymes.JGH Open. 2022 Nov 3;6(12):846-853. doi: 10.1002/jgh3.12831. eCollection 2022 Dec. JGH Open. 2022. PMID: 36514498 Free PMC article.
-
PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes.Inflamm Bowel Dis. 2016 Jan;22(1):134-40. doi: 10.1097/MIB.0000000000000569. Inflamm Bowel Dis. 2016. PMID: 26355465 Free PMC article.
-
Saposhnikovia divaricata root and its major components ameliorate inflammation and altered gut microbial diversity and compositions in DSS-induced colitis.Integr Med Res. 2023 Dec;12(4):100998. doi: 10.1016/j.imr.2023.100998. Epub 2023 Oct 19. Integr Med Res. 2023. PMID: 38024289 Free PMC article.
-
Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.World J Gastroenterol. 2017 Jun 14;23(22):4102-4111. doi: 10.3748/wjg.v23.i22.4102. World J Gastroenterol. 2017. PMID: 28652663 Free PMC article.
-
Hepatobiliary manifestations in children with inflammatory bowel disease: A single-center experience in a low/middle income country.World J Gastrointest Pharmacol Ther. 2020 Aug 8;11(3):48-58. doi: 10.4292/wjgpt.v11.i3.48. World J Gastrointest Pharmacol Ther. 2020. PMID: 32844043 Free PMC article.
References
-
- Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598–1619. - PubMed
-
- Loftus EV, Jr, Sandborn WJ, Lindor KD, LaRusso NF. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis. 1997;3:288–302. - PubMed
-
- Gisbert JP, Luna M, González-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106–1114. - PubMed
-
- Mendes FD, Levy C, Enders FB, Loftus EV, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102:344–350. - PubMed
-
- Heikius B, Niemelä S, Lehtola J, Karttunen T, Lähde S. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol. 1997;32:153–161. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous